Dasatinib Accord (dasatinib (anhydrous))
Generic
- Region
- 🇪🇺 EU
- Active substance
- dasatinib (anhydrous)
- Company
- Accord Healthcare S.L.U.
- Status
- Withdrawn
- Therapeutic area
- Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- CHMP opinion
- Thu 27 Jan 2022
- EU approval
- Thu 24 Mar 2022
- Designations
- Generic
- Application
- EMEA/H/C/005446
- ATC
- L01EA02
- Official record
- www.ema.europa.eu
Indication
Dasatinib Accord is indicated for the treatment of adult patients with: • Ph+ acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy. Dasatinib Accord is indicated for the treatment of paediatric patients with: • newly diagnosed Ph+ ALL in combination with chemotherapy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Sprycel Authorised · Bristol-Myers Squibb Pharma EEIG
- 🇪🇺 Dasatinib Accordpharma Withdrawn · Accord Healthcare S.L.U.
Follow Dasatinib Accord
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.